

## United States Patent and Trademark Office



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

| APPLICATION NO.                           | FILING DATE     | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO.     | CONFIRMATION NO. |  |
|---|-----------------|----------------------|-------------------------|------------------|--|
| 09/937,946                                | 10/07/2002      | Richard J Roman      | 65005391533             | 8704             |  |
| 7   | 7590 04/19/2005 |                      |                         | EXAMINER         |  |
| Zhibin Ren                                |                 |                      | SWOPE, SHERIDAN         |                  |  |
| Quarles & Brady 411 East Wisconsin Aveneu |                 |                      | ART UNIT                | PAPER NUMBER     |  |
| Suite 2040<br>Milwaukee, WI 53202-4497    |                 |                      | 1652                    |                  |  |
|   |                 |                      | DATE MAILED: 04/19/2005 |                  |  |

Please find below and/or attached an Office communication concerning this application or proceeding.

|  | Application No.  | Applicant(s)                     |  |  |  |  |
|--|--|----------------------------------|--|--|--|--|
|  | 09/937,946   | ROMAN ET AL.                     |  |  |  |  |
| Office Action Summary  | Examiner   | Art Unit                         |  |  |  |  |
|  | Sheridan L. Swope  | 1652                             |  |  |  |  |
| The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply   |  |                                  |  |  |  |  |
| A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). |  |                                  |  |  |  |  |
| Status   |  |                                  |  |  |  |  |
| 1) Responsive to communication(s) filed on   | ,  |                                  |  |  |  |  |
|  | —<br>s action is non-final.  |                                  |  |  |  |  |
| 3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is  |  |                                  |  |  |  |  |
| closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.  |  |                                  |  |  |  |  |
| Disposition of Claims  | , ,  |                                  |  |  |  |  |
| 4)⊠ Claim(s) <u>1-34</u> is/are pending in the application.  |  |                                  |  |  |  |  |
| 4a) Of the above claim(s) is/are withdrawn from consideration.   |  |                                  |  |  |  |  |
| 5) Claim(s) is/are allowed.  |  |                                  |  |  |  |  |
| 6)☐ Claim(s) is/are rejected.  |  |                                  |  |  |  |  |
| 7) Claim(s) is/are rejected.   |  |                                  |  |  |  |  |
| _ ,,   | 8) Claim(s) 1-34 are subject to restriction and/or election requirement. |                                  |  |  |  |  |
| Old Claim(s) 1-54 are subject to restriction and/or election requirement.  |  |                                  |  |  |  |  |
| Application Papers   |  |                                  |  |  |  |  |
| 9)☐ The specification is objected to by the Examiner.  |  |                                  |  |  |  |  |
| 10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.  |  |                                  |  |  |  |  |
| Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  |  |                                  |  |  |  |  |
| Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).   |  |                                  |  |  |  |  |
| 11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.  |  |                                  |  |  |  |  |
| Priority under 35 U.S.C. § 119   |  |                                  |  |  |  |  |
| 12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).   |  |                                  |  |  |  |  |
| a) ☐ All b) ☐ Some * c) ☐ None of:   |  |                                  |  |  |  |  |
| 1. Certified copies of the priority documents have been received.  |  |                                  |  |  |  |  |
| 2. Certified copies of the priority documents have been received in Application No   |  |                                  |  |  |  |  |
| Copies of the certified copies of the priority documents have been received in this National Stage   |  |                                  |  |  |  |  |
| application from the International Bureau (PCT Rule 17.2(a)).  |  |                                  |  |  |  |  |
| * See the attached detailed Office action for a list of the certified copies not received.   |  |                                  |  |  |  |  |
| occ the attached detailed office action for a list   | of the certified copies not receive                                      |                                  |  |  |  |  |
|  |  |                                  |  |  |  |  |
| Attachment(s)  |  |                                  |  |  |  |  |
| 1) Notice of References Cited (PTO-892)  4) Interview Summary (PTO-413)  |  |                                  |  |  |  |  |
| 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)  Paper No(s)/Mail Date  3) Information Disclosure Statement(s) (PTO-1449 or PTO/SR/08)  5) Notice of Informal Patent Application (PTO-152)   |  |                                  |  |  |  |  |
| 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date   | 6) Other:  |                                  |  |  |  |  |
| U.S. Patent and Trademark Office PTOL-326 (Rev. 1-04) Office Ac  | etion Summary  | Part of Paper No./Mail Date 0405 |  |  |  |  |

Application/Control Number: 09/937,946

Art Unit: 1652

## **DETAILED ACTION**

Claim 1-34 are pending.

## Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, Claims 4–26, drawn to a method of treatment using a 20-HETE synthesizing enzyme inhibitor.

Group II, Claims 27-34, drawn to a method of treatment using an inhibitor of 20-HETE synthesizing enzyme expression.

For each of Inventions I and II above, restriction to one of the following is also required under 35 USC 121 and 327. Therefore, election is required of one of Inventions I and II and one of Inventions (A)-(K).

For Invention I, elect one of:

- (A) HET0016
- (B) 17-ODYA
- (C) dibromododecenyl methylsulfimide
- (D) 1-aminobenzotriazole
- (E) miconazole
- (F) an antibody to a 20-HETE synthesizing enzyme
- (G) a CYP4A inhibitor

For Invention II, elect one of:

(H) SEQ ID NO: 1

(I) SEQ ID NO: 3

(J) SEQ ID NO: 2

(K) SEQ ID NO: 4

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical feature for the following reasons: The technical feature linking Groups I and II appears to be that they all relate to HETE synthesizing enzymes. However, Alonso-Galicia et al, 1997 (IDS) teach treatment with dibromododecenyl methylsulfimide (Fig 1), which anticipates Claims 1, 5, and 25. Therefore Groups I and II share no special technical feature as defined by PCT Rule 13.2, as it does not define a contribution over the prior art. Furthermore, the methods of Groups I and II do not use the same reagents or produce the same results. Accordingly, Groups I and II are not so linked by the same or a corresponding special technical feature as to form a single general inventive concept.

Searching both of Groups I and II would represent a burden on the Office because the methods of Groups I and II do not recite the same steps and products used, and/or results produced.

These inventions lack Unity of Invention for the reasons given above. Furthermore, each invention has acquired a separate status in the art due to their recognized divergent subject matter and, thus, searching more than one invention would be a burden on the Office. Therefore, restriction for examination purposes, as indicated, is proper.

Claims 1-3 link Inventions I and II. The restriction requirement restricting the linked inventions is subject to the nonallowance of the linking claims, Claims 1-3. Upon the allowance of the linking claims, the restriction requirement as to the linked inventions shall be withdrawn and any claims depending from or otherwise including all the limitations of the allowable linking claims will be entitled to examination in the instant application. Applicants are advised that if any such claims depending from or including all the limitations of the allowable linking claims is/are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sheridan L. Swope whose telephone number is 571-272-0943. The examiner can normally be reached on M-F; 9:30-7 EST.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy can be reached on 571-272-0928. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 09/937,946 Page 5

Art Unit: 1652

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published application may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <a href="http://pair-direct.uspto.gov">http://pair-direct.uspto.gov</a>. Should you have questions on the access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Sheridan Lee Swope, Ph.D.

Showden Swape